BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $RYTM readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06760546-pcd@datacutoff.com
DTSTAMP:20261120T191202Z
DTSTART;VALUE=DATE:20270313
DTEND;VALUE=DATE:20270314
SUMMARY:Setmelanotide readout (P3) · Rhythm Pharmaceuticals\, Inc. $RYTM
DESCRIPTION:A Trial of Setmelanotide in Patients With Congenital Hypothalam
 ic Obesity (Sub-study of NCT05774756)\n\nPrimary completion date: 2027-03-
 13 (estimated)\nOriginally planned: 2027-01-30 (+1.4 months)\nPhase 3 · C
 ardio-Met · Hypothalamic Obesity\, Multiple Pituitary Hormone Deficiency 
 Genetic Form\, Septo-Optic Dysplasia\nEnrollment: 39 · Sites: 11\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?n
 ct=NCT06760546\nhttps://clinicaltrials.gov/study/NCT06760546
URL:https://datacutoff.com/radar.html?nct=NCT06760546
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
